IDH1 and myelodysplastic syndrome: DiNardo et al. investigated the efficacy of enasidenib in MDS harboring an IDH-2 mutation in a phase II trial with 2 arms: enasidenib in combination with azacitidine as an upfront therapy or as a monotherapy in those previously treated with HMA.